Following Glaukos’ (GKOS) earnings report, attention now turns to the regulatory processes for core growth products like iDose and iStent Infinite, outlined more broadly in our March 1 deep dive on issues surrounding their approval, coding, coverage, and reimbursement.
Glaukos (GKOS): Pipeline Policy Pathway
Want to learn more? Download the Report.
Identify opportunity and risks driven by public policy.
Size of Medicare Advantage mitigation may be less than earlier expectations...Read more